Suppr超能文献

台湾幽门螺杆菌继发性抗生素耐药性的五年连续变化

Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan.

作者信息

Wu I-Ting, Chuah Seng-Kee, Lee Chen-Hsiang, Liang Chih-Ming, Lu Lung-Sheng, Kuo Yuan-Hung, Yen Yi-Hao, Hu Ming-Luen, Chou Yeh-Pin, Yang Shih-Cheng, Kuo Chung-Mou, Kuo Chung-Huang, Chien Chun-Chih, Chiang Yu-Shao, Chiou Shue-Shian, Hu Tsung-Hui, Tai Wei-Chen

机构信息

I-Ting Wu, Seng-Kee Chuah, Chih-Ming Liang, Lung-Sheng Lu, Yuan-Hung Kuo, Yi-Hao Yen, Ming-Luen Hu, Yeh-Pin Chou, Shih-Cheng Yang, Chung-Mou Kuo, Chung-Huang Kuo, Shue-Shian Chiou, Tsung-Hui Hu, Wei-Chen Tai, Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.

出版信息

World J Gastroenterol. 2015 Oct 7;21(37):10669-74. doi: 10.3748/wjg.v21.i37.10669.

Abstract

AIM

To determine changes in the antibiotic resistance of Helicobacter pylori (H. pylori) in southern Taiwan after failure of first-line standard triple therapy.

METHODS

We analyzed 137 H. pylori-infected isolates from patients who experienced eradication failure after standard first-line triple therapy from January 2010 to December 2014. The H. pylori strains were tested for susceptibility to amoxicillin, clarithromycin, levofloxacin, metronidazole and tetracycline using the E-test method. The minimal inhibitory concentration (MIC) was determined by the agar dilution test. MIC values of ≥ 0.5, ≥ 1, ≥ 1, ≥ 4 and ≥ 8 mg/L were considered to be the resistance breakpoints for amoxicillin, clarithromycin, levofloxacin, tetracycline and metronidazole, respectively.

RESULTS

A high resistance rate was found for clarithromycin (65%-75%) and metronidazole (30%-40%) among patients who failed first-line standard therapy. The resistance levels to amoxicillin and tetracycline remained very low; however, levofloxacin resistance was as high as 37.5% in 2010 but did not increase any further during the past 5 years. The rates of resistance to these antibiotics did not show a statistically significant upward or downward trend.

CONCLUSION

Antibiotic resistance of H. pylori remains a problem for the effective eradication of this pathogen and its associated diseases in Taiwan. High clarithromycin resistance indicated that this antibiotic should not be prescribed as a second-line H. pylori eradication therapy. Moreover, levofloxacin-based second-line therapy should be used cautiously, and the local resistance rates should be carefully monitored.

摘要

目的

确定台湾南部一线标准三联疗法失败后幽门螺杆菌(H. pylori)的抗生素耐药性变化。

方法

我们分析了2010年1月至2014年12月期间经历标准一线三联疗法根除失败的患者的137株幽门螺杆菌感染分离株。采用E-test法检测幽门螺杆菌菌株对阿莫西林、克拉霉素、左氧氟沙星、甲硝唑和四环素的敏感性。通过琼脂稀释试验确定最低抑菌浓度(MIC)。阿莫西林、克拉霉素、左氧氟沙星、四环素和甲硝唑的MIC值分别≥0.5、≥1、≥1、≥4和≥8 mg/L被视为耐药断点。

结果

一线标准治疗失败的患者中,克拉霉素(65%-75%)和甲硝唑(30%-40%)的耐药率较高。对阿莫西林和四环素的耐药水平仍然很低;然而,左氧氟沙星耐药率在2010年高达37.5%,但在过去5年中没有进一步增加。这些抗生素的耐药率没有显示出统计学上显著的上升或下降趋势。

结论

幽门螺杆菌的抗生素耐药性仍然是台湾有效根除该病原体及其相关疾病的一个问题。高克拉霉素耐药性表明该抗生素不应作为二线幽门螺杆菌根除疗法使用。此外,基于左氧氟沙星的二线疗法应谨慎使用,并应密切监测当地的耐药率。

相似文献

1
Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan.
World J Gastroenterol. 2015 Oct 7;21(37):10669-74. doi: 10.3748/wjg.v21.i37.10669.
2
Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Infection in the Dominican Republic.
Am J Trop Med Hyg. 2017 May;96(5):1050-1059. doi: 10.4269/ajtmh.16-0729. Epub 2017 Feb 13.
3
Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan.
J Gastroenterol Hepatol. 2009 Jul;24(7):1230-5. doi: 10.1111/j.1440-1746.2009.05829.x. Epub 2009 May 19.
6
7
Novel and Effective Therapeutic Regimens for in an Era of Increasing Antibiotic Resistance.
Front Cell Infect Microbiol. 2017 May 5;7:168. doi: 10.3389/fcimb.2017.00168. eCollection 2017.
9
Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis.
Lancet Gastroenterol Hepatol. 2017 Oct;2(10):707-715. doi: 10.1016/S2468-1253(17)30219-4. Epub 2017 Aug 7.
10
Antimicrobial susceptibility of clinical isolates and its eradication by standard triple therapy: a study in west central region of Colombia.
Microbiol Spectr. 2024 Aug 6;12(8):e0040124. doi: 10.1128/spectrum.00401-24. Epub 2024 Jun 25.

引用本文的文献

1
Research progress of potassium-competitive acid blockers in the treatment of .
Ann Med. 2025 Dec;57(1):2544886. doi: 10.1080/07853890.2025.2544886. Epub 2025 Aug 12.
2
Molecular surveillance of species with high prevalence from two streams with various wastewater pollution in Taiwan.
One Health. 2024 May 16;18:100757. doi: 10.1016/j.onehlt.2024.100757. eCollection 2024 Jun.
3
Update on the second-line treatment of infection: a narrative review.
Therap Adv Gastroenterol. 2023 Sep 4;16:17562848231192750. doi: 10.1177/17562848231192750. eCollection 2023.
4
The prevalence of clarithromycin-resistant isolates: a systematic review and meta-analysis.
PeerJ. 2023 Mar 30;11:e15121. doi: 10.7717/peerj.15121. eCollection 2023.
5
Prevalence, diversity and public health implications of species in pet and stray dogs.
One Health. 2022 Aug 29;15:100430. doi: 10.1016/j.onehlt.2022.100430. eCollection 2022 Dec.
6
Evodiamine Inhibits Growth and -Induced Inflammation.
Int J Mol Sci. 2021 Mar 25;22(7):3385. doi: 10.3390/ijms22073385.
7
Phenotypic and Genotypic Antibiotic Resistance Patterns in Strains From Ethnically Diverse Population in México.
Front Cell Infect Microbiol. 2021 Feb 11;10:539115. doi: 10.3389/fcimb.2020.539115. eCollection 2020.
8
Trend of changes in antibiotic resistance in from 2013 to 2019: a multicentre report from Taiwan.
Therap Adv Gastroenterol. 2020 Dec 10;13:1756284820976990. doi: 10.1177/1756284820976990. eCollection 2020.
9
First-line eradication rates are significantly lower in patients with than those without type 2 diabetes mellitus.
Infect Drug Resist. 2019 May 29;12:1425-1431. doi: 10.2147/IDR.S194584. eCollection 2019.
10
Inhibitory Effects of Menadione on Growth and -Induced Inflammation via NF-κB Inhibition.
Int J Mol Sci. 2019 Mar 7;20(5):1169. doi: 10.3390/ijms20051169.

本文引用的文献

2
High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection.
Clin Gastroenterol Hepatol. 2015 May;13(5):895-905.e5. doi: 10.1016/j.cgh.2014.10.036. Epub 2014 Nov 14.
3
Quinolone-containing therapies in the eradication of Helicobacter pylori.
Biomed Res Int. 2014;2014:151543. doi: 10.1155/2014/151543. Epub 2014 Aug 28.
6
Treatment of Helicobacter pylori infection: current status and future concepts.
World J Gastroenterol. 2014 May 14;20(18):5283-93. doi: 10.3748/wjg.v20.i18.5283.
7
Second and third line treatment options for Helicobacter pylori eradication.
World J Gastroenterol. 2014 Feb 14;20(6):1517-28. doi: 10.3748/wjg.v20.i6.1517.
8
How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?
World J Gastroenterol. 2013 Dec 7;19(45):8168-80. doi: 10.3748/wjg.v19.i45.8168.
9
Current recommendations for Helicobacter pylori therapies in a world of evolving resistance.
Gut Microbes. 2013 Nov-Dec;4(6):541-8. doi: 10.4161/gmic.25930. Epub 2013 Aug 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验